

UvA-DARE (Digital Academic Repository)

Increased colorectal cancer risk during follow-up in patients with hyperplastic polyposis syndrome: a multicentre cohort study

Boparai, K.S.; Mathus-Vliegen, E.M.H.; Koornstra, J.J.; Nagengast, F.M.; van Leerdam, M.; van Noesel, C.J.M.; Houben, M.; Cats, A.; van Hest, L.P.; Fockens, P.; Dekker, E.

DOI

[10.1136/gut.2009.185884](https://doi.org/10.1136/gut.2009.185884)

Publication date

2010

Document Version

Final published version

Published in

Gut

[Link to publication](#)

Citation for published version (APA):

Boparai, K. S., Mathus-Vliegen, E. M. H., Koornstra, J. J., Nagengast, F. M., van Leerdam, M., van Noesel, C. J. M., Houben, M., Cats, A., van Hest, L. P., Fockens, P., & Dekker, E. (2010). Increased colorectal cancer risk during follow-up in patients with hyperplastic polyposis syndrome: a multicentre cohort study. *Gut*, 59(8), 1094-1100. <https://doi.org/10.1136/gut.2009.185884>

General rights

It is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), other than for strictly personal, individual use, unless the work is under an open content license (like Creative Commons).

Disclaimer/Complaints regulations

If you believe that digital publication of certain material infringes any of your rights or (privacy) interests, please let the Library know, stating your reasons. In case of a legitimate complaint, the Library will make the material inaccessible and/or remove it from the website. Please Ask the Library: <https://uba.uva.nl/en/contact>, or a letter to: Library of the University of Amsterdam, Secretariat, Singel 425, 1012 WP Amsterdam, The Netherlands. You will be contacted as soon as possible.

UvA-DARE is a service provided by the library of the University of Amsterdam (<https://dare.uva.nl>)

Increased colorectal cancer risk during follow-up in patients with hyperplastic polyposis syndrome: a multicentre cohort study

Karam S Boparai,¹ Elisabeth M H Mathus-Vliegen,¹ Jan J Koornstra,² Fokko M Nagengast,³ Monique van Leerdam,⁴ Carel J M van Noesel,⁵ Martin Houben,⁶ Annemieke Cats,⁷ Liselotte P van Hest,⁸ Paul Fockens,¹ Evelien Dekker¹

See Commentary, p 1019

¹Departments of Gastroenterology and Hepatology, Academic Medical Center, University of Amsterdam, The Netherlands

²Department of Gastroenterology and Hepatology, University Medical Center Groningen, Groningen, The Netherlands

³Department of Gastroenterology and Hepatology, Radboud University Medical Center, Nijmegen, The Netherlands

⁴Department of Gastroenterology and Hepatology, Erasmus Medical Center, Rotterdam, The Netherlands

⁵Department of Pathology, Academic Medical Center, University of Amsterdam, The Netherlands

⁶Department of Gastroenterology and Hepatology, Haga Teaching Hospital, The Hague, The Netherlands

⁷Department of Gastroenterology and Hepatology, Antonie van Leeuwenhoek Hospital, The Netherlands

⁸Department of Clinical Genetics, VU Medical Center, Amsterdam, The Netherlands

Correspondence to

Dr Evelien Dekker, Department of Gastroenterology and Hepatology, Academic Medical Center, Meibergdreef 9, Amsterdam 1105 AZ, The Netherlands; e.dekker@amc.uva.nl

Revised 7 July 2009

Accepted 4 August 2009

Published Online First

25 August 2010

ABSTRACT

Background and aims Patients with hyperplastic polyposis syndrome (HPS) receive endoscopic surveillance to prevent malignant progression of polyps. However, the optimal treatment and surveillance protocol for these patients is unknown. The aim of this study was to describe the clinical and pathological features of a large HPS cohort during multiple years of endoscopic surveillance.

Methods Databases were searched for patients with HPS, who were analysed retrospectively. Endoscopy reports and histopathology reports were collected to evaluate frequency of endoscopic surveillance and to obtain information regarding polyp and the presence of colorectal cancer (CRC).

Results In 77 patients with HPS, 1984 polyps were identified during a mean follow-up period of 5.6 years (range: 0.5–26.6). In 27 (35%) patients CRC was detected of which 22 (28.5%) at initial endoscopy. CRC was detected during surveillance in five patients (cumulative incidence: 6.5%) after a median follow-up time of 1.3 years and a median interval of 11 months. Of these interval CRCs, 4/5 were detected in diminutive serrated polyps (range: 4–16 mm). The cumulative risk of CRC under surveillance was 7% at 5 years. At multivariate logistic regression, an increasing number of hyperplastic polyps (OR 1.05, $p=0.013$) and serrated adenomas (OR 1.09, $p=0.048$) was significantly associated with CRC presence.

Conclusions HPS patients undergoing endoscopic surveillance have an increased CRC risk. The number of serrated polyps is positively correlated with the presence of CRC in HPS, thus supporting a 'serrated pathway' to CRC. To prevent malignant progression, adequate detection and removal of all polyps seems advisable. If this is not feasible, surgical resection should be considered.

INTRODUCTION

Colorectal cancer (CRC) ranks as the third most common cause of cancer-related death in the Western world.¹ A well known mechanism describing CRC development is the adenoma–carcinoma sequence which, in the majority of cases, is initiated by activation of the Wnt signalling pathway.^{2–3} Much information regarding this pathway has been derived from polyposis syndromes such as familial adenomatous polyposis (FAP) and MYH-

associated polyposis (MAP). In addition to this classical adenoma–carcinoma sequence, a proposed 'serrated neoplasia pathway', describes the progression of serrated polyps (ie, hyperplastic polyps, sessile serrated adenomas and traditional serrated adenomas) to CRC.⁴ It is proposed that this possible alternative pathway is also associated with hyperplastic polyposis syndrome (HPS). There are strong indications that mixed pathways also exist in which both conventional adenomas and serrated polyps are involved.⁵

Clinically, the condition HPS is characterised by the presence of multiple hyperplastic polyps (HPs) spread throughout the colorectum and is associated with an increased risk of CRC. Indeed, numerous patients with CRC and concurrent HPS have been reported.^{6–12} While previously the indicated management of patients with HPS was unknown, experts presently believe that these patients should undergo regular endoscopic surveillance to prevent malignant progression of polyps.^{7–13} However, the optimal treatment and surveillance protocol for HPS patients is largely speculative. Therefore it seems possible that a proportion of patients with HPS may be insufficiently treated and consequently be at risk of developing CRC under surveillance (interval CRC).

The aim of this study was to describe the clinical and pathological features of a large HPS cohort ($n=77$) during multiple years of endoscopic surveillance. Furthermore, we assessed the cumulative incidence and incidence rate of CRC during surveillance and its association with the interval and frequency of surveillance endoscopies. Finally, we analysed possible predictive variables that may be associated with the occurrence of CRC in HPS.

PATIENTS AND METHODS

Study population

Databases of seven medical centres in the Netherlands were searched for patients satisfying the diagnostic criteria of HPS (ie, at least five histologically diagnosed HPs proximal to the sigmoid colon, of which two greater than 10 mm in diameter, or more than 20 HPs distributed throughout the colon) and undergoing endoscopic surveillance.^{8–11} Owing to the common presence of both HPs and (sessile) serrated adenomas (SAs) in HPS and the difficult histological differentiation between these two groups, both HPs and SAs were

used to fulfil the criteria.^{14–17} Of these patients, clinical data from May 1982 to June 2008 were analysed retrospectively. Adherence to the described criteria was assessed by analysing endoscopy reports with corresponding histopathology reports as well as histopathology reports of colonic surgical resection specimens. Patients with a known germline *APC* mutation or bi-allelic *MYH* mutation were excluded from the study.

Clinical characteristics

Demographic data of patients concerning age, sex and history of CRC were ascertained. Endoscopy reports with corresponding histopathology reports during follow-up were collected to evaluate the duration, interval and frequency of endoscopic surveillance and to derive information regarding the, number, size, distribution and histology of polyps. If applicable, histopathology reports of surgical colonic resection specimens were also used to obtain the above mentioned polyp characteristics. Also, if genetic mutation analysis was performed, these data were retrieved.

Polyps were classified as HP, serrated adenoma (SA), mixed polyp (MP) or conventional adenoma. Because the distinction between sessile serrated adenoma and traditional serrated adenoma had not been made throughout the study period by each medical center and because they are both considered to be precursor lesions in the 'serrated pathway', the category SAs comprised both types of lesions.¹⁶ Regarding the number of polyps detected in this study, all polyps were tallied once, ie, when a detected polyp was not removed during endoscopy this polyp was not re-tallied at subsequent endoscopies.

Information concerning the nature and reason of performed colorectal surgery was obtained if applicable. Detailed information regarding co-existent CRC and CRC incidence during surveillance was examined by evaluating histopathology reports of colectomy resection specimens and/or endoscopy reports. An interval CRC was defined as a CRC detected after HPS diagnosis after at least two previous endoscopies.

Statistical analysis

Statistical analyses were performed by using a statistical software package (SPSS 15.0.1). The cumulative risk of developing CRC during follow-up was analysed by Kaplan–Meier survival analysis. Observation time was measured from date of HPS diagnosis to the incidence of carcinoma or end of the study period. Univariate binary logistic regression was performed for chosen variables that may be associated with the presence of CRC. For multivariate regression analyses, only variables which showed an association ($p < 0.1$) on univariate analysis were used in a final multivariate model.

RESULTS

Patients

Data of 77 patients with HPS from the period 1982–2008 were analysed retrospectively in this study. Clinical characteristics of patients are shown in table 1. The median age at diagnosis of HPS was 56 years (range: 40–74). There were 42 males and 35 females. Fifty-nine of 77 patients (77%) had >5 proximal HPs (of which two were larger than 10 mm) or >20 HPs spread throughout the colon. The other 17 patients had >5 proximal HPs/SAs (of which two were larger than 10 mm) or >20 HPs/SAs spread throughout the colon. In 52/77 (68%) patients, germline *APC* and *MYH*-mutation analysis was performed. In all cases mutation analysis was negative except for one patient with a mono-allelic *MYH*-mutation (Y165C) who had ≥ 15 adenomas. In all patients harbouring ≥ 15 adenomas ($n=5$)

mutation analysis was performed. The main reasons for initial presentation were colorectal polyps detected elsewhere ($n=23$), a positive family history for CRC or colorectal polyps ($n=16$), bloody stools/positive faecal occult blood test/iron-deficiency anaemia ($n=15$), altered defaecation pattern ($n=8$), abdominal pain with or without altered bowel habits ($n=5$), polyps detected at sigmoidoscopy screening programme ($n=4$), and personal history of CRC ($n=3$).

Cumulatively, a median number of 15 HPs per patient were found in this cohort. In 47 (61%) patients HPs ≥ 10 mm were detected. SAs and adenomas were identified in 52% and 69% of patients, respectively. CRC was diagnosed in 27 (35%) patients: 22 (28.5%) at initial endoscopy and 5 (6.5%) during follow-up.

A surgical colonic resection was performed in 33/77 (43%) patients: two total colectomies, 13 subtotal colectomies, eight hemi-colectomies (six left-sided) and 10 (recto)sigmoidal resections. Seven patients underwent a surgical resection because of extensive polyposis or due to difficult advancement of the endoscope during examination resulting in incomplete visualisation of the colon. The other 26 patients underwent a colonic resection due to CRC diagnosis. Consequently, during (a part of) follow-up 44 patients received endoscopic surveillance of the intact colon; 17 patients of the remaining segment proximal to the rectosigmoid colon; 15 patients of the remaining distal colon segment and two patients did not receive endoscopic surveillance after undergoing a proctocolectomy.

The mean follow-up period of patients was 5.6 years (range: 0.5–26.6) and from the point HPS was diagnosed this was 4.0 years (range: 0.4–21.0). During follow-up, the number of surveillance endoscopies varied among patients. In the time period observed, 207 surveillance endoscopies were performed (median 3, range 0–11). One patient was diagnosed with HPS based on the surgical resection specimen and had not yet undergone surveillance endoscopies. The median interval between surveillance endoscopies was 10 months (range: 1–96).

Polyps

Polyp characteristics are outlined in table 1. In this study, 847/1407 (60%) HPs, 197/302 (65%) SSAs and 165/273 (60%) adenomas were detected proximal to the sigmoid colon. The maximum size of HPs and SAs was 30 mm which were located in the ascending and transverse colon, respectively. The largest adenoma detected in this cohort was 75 mm, which was located in the ascending colon. Polyps were detected during endoscopy with standard or high-resolution white-light endoscopy. Narrow-band imaging was used in 22/294 (7%) endoscopies in 22 patients.

Colorectal cancer

Of the 77 HPS patients included in this study, 27 (35%) patients had CRC (median age 56 years; range 36–75). In 14/27 (52%) of these patients, CRC was located proximal to the sigmoid colon. One patient had two separate synchronous CRCs, one proximally and one distally located.

While CRC was diagnosed at initial colonoscopy in the majority (22/27) of HPS patients, in five patients (cumulative incidence: 6.5%) with a median age of 58 years (range 49–68) CRC was detected during surveillance after the diagnosis HPS was made (mean follow-up time 5.6 years) without any prior history of CRC. The median follow-up time in this group was 1.3 years (range: 0.4–6.7) with a median of three endoscopies (range: 2–4). Clinical and histological data of these patients are summarised in table 2. During a total of 294.6 person years of follow-up, this corresponds with a CRC incidence rate during

Table 1 Characteristics of patients with hyperplastic polypoid syndrome (HPS) from multiple centres in The Netherlands, divided per centre

	All centres (n = 77)	Centre 1 (n = 43)	Centre 2 (n = 8)	Centre 3 (n = 7)	Centre 4 (n = 6)	Centre 5 (n = 5)	Centre 6 (n = 5)	Centre 7 (n = 3)
Median age at diagnosis (range)	56 (40–74)	55 (40–74)	51 (42–69)	56 (46–65)	58 (56–67)	51 (43–72)	52 (45–61)	57 (48–69)
Mean follow-up time in years (range)	5.6 (0.5–26.6)	4.4 (1.3–9.3)	10.6 (2.9–26.4)	6.4 (1.1–12.3)	2.6 (1.2–5.1)	4.3 (3.0–5.7)	2.2 (1.5–4.1)	4.4 (1.3–9.3)
Mean follow-up time after HPS diagnosis in years (range)	4.0 (0.4–21.0)	3.2 (1.3–6.1)	8.1 (1.1–20.8)	5.8 (1.1–11.7)	2.1 (1.2–4.4)	3.3 (1.9–4.7)	2.2 (1.5–4.1)	3.2 (1.3–6.1)
Median interval endoscopies in months (range)	11 (1–96)	9 (1–96)	23 (5–26)	7 (3–63)	6 (1–17)	8 (1–24)	11 (3–53)	13 (10–25)
Median number of HPs in patients (range)	15 (2–53)	14 (2–53)	29 (11–73)	25 (6–45)	10 (6–27)	12 (2–22)	21 (9–41)	16 (5–18)
Median number of proximal HPs in patients (range)	8 (1–45)	7 (1–30)	29 (5–45)	10 (2–21)	7 (2–12)	6 (2–12)	10 (4–30)	5 (5–13)
Number of patients with an HP > 10 mm	47 (61%)	25 (58%)	5 (63%)	5 (71%)	3 (50%)	4 (80%)	4 (80%)	1 (33%)
Patients with > 1 SA	40 (52%)	32 (74%)	1 (13%)	2 (29%)	1 (17%)	3 (60%)	0	1 (33%)
Median number of SAs in patients (range)	1 (0–24)	5 (0–24)	0 (0–6)	0 (0–8)	0 (0–1)	1 (0–20)	0	0 (0–1)
Patients with > 1 adenoma	53 (69%)	31 (72%)	6 (75%)	6 (86%)	3 (50%)	4 (80%)	3 (60%)	0 (0–1)
Median number of adenomas in patients (range)	2 (0–26)	2 (0–26)	2 (0–16)	6 (0–14)	1 (0–9)	2 (0–3)	1 (0–5)	0 (0–7)
Patients with CRC	27 (35%)	15 (35%)	6 (75%)	3 (43%)	1 (17%)	0	0	2 (67%)
At initial endoscopy	22 (28.5%)	11 (73%)	6 (100%)	2 (67%)	1 (100%)	0	0	2 (100%)
Interval CRC	5 (6.5%)	4 (27%)	0	1 (33%)	0	0	0	0
Total polyps	1984	1124	295	216	87	93	117	50
Number of HPs	1407 (72%)	705 (63%)	258 (87%)	161 (74%)	74 (85%)	61 (67%)	109 (93%)	39 (78%)
Number of SAs	302 (15%)	259 (23%)	6 (2%)	9 (4%)	1 (1%)	23 (25%)	0	4 (8%)
Number of MPs	2 (0.1%)	2 (0.2%)	0	0	0	0	0	0
Number of adenomas	273 (14%)	160 (14%)	31 (11%)	46 (22%)	12 (14%)	9 (8%)	8 (7%)	7 (14%)

CRC, colorectal cancer; HPs, hyperplastic polyps; SAs, serrated adenomas.

Table 2 Characteristics of patients with hyperplastic polyposis syndrome (HPS) in which an interval carcinoma was detected

Patient	Age	Sex	Number of endoscopies until CRC	Location CRC	Size CRC (TMM)	Immediate adjacent polyps	Time (months) between HPS diagnosis and CRC detection	Time (months) between last endoscopy and diagnosis CRC	Most proximal intubation point last endoscopy	Abnormalities and treatment during last endoscopy before diagnosis CRC
1	49	M	2	Ascending colon	16 mm (T3N0M0)	SA	11.4	7.7	Caecum	>20 polyps which were only diagnostically biopsied.
2	67	F	3	Ascending colon	95 mm (T3N0M0)	None	80.4	44.2	Transverse colon	Multiple polyps throughout the colorectum. Procedure complicated by perforation (aborted). Multiple polyps remained in situ. Patient returned with symptoms after 44.2 months.
3	58	M	4	Rectum	4 mm (TisN0M0)	HP	36.4	11.6	Sigmoid (subtotal colectomy)	All visible rectosigmoidal polyps removed.
4	48	M	2	Transverse colon	10 mm (T1N0M0)	HP	4.3	4.3	Caecum	Multiple polyps detected, of which 11 polyps were removed. Multiple polyps remained in situ
5	48	F	3	Descending colon	Not stated (TisN0M0)	HP	15.6	10.1	Caecum	Multiple polyps throughout the colorectum, which were only diagnostically biopsied

CRC, colorectal cancer; HP, hyperplastic polyp; SA, serrated adenoma.

surveillance of 17 per 1000 person-years. In four of the five (80%) patients, CRC was detected during a planned endoscopy and was located within a HP (3/4) or a SA (1/4) without causing clinical symptoms. The median size of these polyps was 10 mm (range: 4–16 mm). One patient (patient 2) presented with weight loss and fatigue after a surveillance interval of more than 3 years. At endoscopy a large CRC was detected. In four of five patients, CRC was located proximally to the sigmoid colon. The median interval between surveillance endoscopies in patients with an interval CRC was 11 months (range: 3–43) compared to 10 months (range: 1–96) in HPS patients without an interval CRC (NS). The median interval between the last surveillance endoscopy and CRC detection in patients with interval carcinomas was also 11 months (range: 4–43). The calculated cumulative risk of CRC in HPS during surveillance was 7% at 5 years (figure 1). When analysing the cumulative risk separately for patients with an intact colon and for patients with a surgical colonic resection, the 5-year cumulative risk was 6% and 4%, respectively.

To analyse an association with CRC in HPS, univariate logistic regression was performed for eight independent variables: age, sex, number of HPs, number of SAs, number of adenomas, largest HP, largest SA and largest adenoma (table 3). At univariate logistic regression, the number of HPs and the number of SAs were associated with CRC ($p<0.1$). At subsequent multivariate logistic regression the number of HPs ($p=0.013$) and the number of SAs ($p=0.048$) were significantly associated with CRC with corresponding OR of 1.05 (95% CI: 1.01 to 1.10) and 1.09 (95% CI 1.00 to 1.19) respectively.

DISCUSSION

This multicentre cohort study showed that in a total of 27/77 (35%) HPS patients, CRC was detected. Interestingly, CRC was detected in 5/77 (6.5%) patients during surveillance of which four CRCs within a diminutive serrated polyp (HP or SA) resulting in a cumulative risk of CRC under endoscopic surveillance of 7% in 5 years. This is substantial considering that the lifetime risk of developing CRC in the general population is estimated to be 6%.¹⁸ Of these patients with interval CRCs, two CRCs were detected within a year (table 2: 11.4 and 4.3 months) after the diagnosis HPS was made and after two previous endoscopies. The high frequency of endoscopies


**Figure 1** Cumulative proportion of patients with hyperplastic polyposis syndrome (HPS) and with colorectal cancer during surveillance.

Table 3 Results of univariate and multivariate logistic regression analysis: independent prognostic variables and corresponding odds ratios for the presence of colorectal cancer in hyperplastic polyposis syndrome

Prognostic variables (univariate analysis)	Odds ratio	95% CI	p Value
Age (per year)	1.04	0.98 to 1.11	0.162
Male sex	0.67	0.26 to 1.72	0.408
Number of HPs (per polyp)	1.05	1.01 to 1.09	0.018*
Number of SAs (per polyp)	1.08	0.99 to 1.17	0.076*
Number of adenomas (per polyp)	1.01	0.92 to 1.11	0.870
Largest HP (per mm)	0.98	0.91 to 1.06	0.611
Largest SA (per mm)	1.03	0.97 to 1.10	0.302
Largest adenoma (per mm)	0.99	0.96 to 1.04	0.887
Prognostic variables (multivariate analysis)	Odds ratio	95% CI	p Value
Number of HPs (per polyp)	1.05	1.01 to 1.10	0.013*
Number of SAs (per polyp)	1.09	1.00 to 1.19	0.048*

*Statistically significant p-value for univariate analysis: $p < 0.1$ and for multivariate analysis: $p < 0.05$.

HPs, hyperplastic polyps; SAs, serrated adenomas.

in a short time period suggest that these patients were probably still in an orientating treatment phase when CRC was detected. If surveillance was defined as endoscopies performed after HPS diagnosis after at least 1-year follow-up, the cumulative risk under surveillance would be 4% at 5 years.

Although different management protocols have recently been advised, thus far no uniform and adequately substantiated management protocol exists for the endoscopic management of HPS patients. Consequently, lack of clarity exists regarding the recommended surveillance interval and which polyps to remove. Recent studies recommend surveillance intervals ranging from 1 to 3 years and concerning the removal of polyps, advice varies from removal of only proximally located polyps to complete removal of all polyps >5 mm.^{7 13}

This absence of a standardised treatment protocol may also be associated with the incidence of interval CRCs in this retrospective multicentre study dating back to 1982. Possible explanations for the incidence of interval CRCs could be that previously an association between HPS and CRC was not made or that only proximal and/or larger lesions were considered clinically significant, resulting in incomplete removal of polyps. Also when considering the relatively short median interval between endoscopies (median interval: 11 months), it is likely that the interval CRCs were also present at prior surveillance endoscopies but were not removed. This was indeed the case for two of five of these patients who underwent incomplete removal of all detected polyps during the last surveillance endoscopy before CRC diagnosis (table 2: patient 2 and 4), underlining the importance of comprehensive polyp removal during surveillance.

Conversely, in three of five patients (patients 1, 3 and 5) all detected polyps were biopsied or removed at previous endoscopy. A possible explanation for this contrary finding could be that these CRCs originating in serrated polyps were simply missed. This could possibly be due to the multiplicity of polyps seen in HPS patients resulting in a sub-optimal overview of all colorectal polyps. Alternatively, typical HPs and (sessile) serrated adenomas seldom exceed 10 mm in size, suggesting that most polyps in HPS are diminutive.^{19–25} It has been shown that the miss-rate of polyps <10 mm can be as high as 23%.²⁶ This could explain why these relatively small CRCs originating in diminutive serrated polyps were not detected at previous endoscopy.

Nevertheless, considering their small size and the unknown progression rate in HPS, it cannot be excluded that these CRCs, originating in serrated polyps (4/5) developed since the last endoscopy. A previous retrospective polyp study of consecutive patients with an average risk for CRC showed that the estimated growth rates of HPs and SAs (both sessile and traditional) compared to conventional adenomas were similar or significantly higher.²⁷ Moreover, a recent case report described the progression of a sessile serrated adenoma to carcinoma within 8 months.²⁸ In this respect, it is conceivable that in HPS a subset of serrated polyps have an increased progression rate leading to CRC. This is an interesting point considering that the risk of high grade dysplasia or even invasive cancer in diminutive lesions (<10 mm) has been shown to be $<2\%$.^{29–31} The finding of CRC within a small serrated polyp in 4/5 (80%) interval carcinomas suggests that in HPS small polyps have a greater malignant potential than in the general population.

When considering the management of patients with HPS, this study suggests that the absence of a clear treatment protocol plays a role in the presence of CRCs during surveillance. Considering that CRCs detected in this study were as small as 4 mm (detected in a HP: patient 3), removal of all polyps seems advisable but needs to be prospectively assessed. Although these recommendations seem of importance in preventing malignant progression in HPS, practical difficulties may present when trying to comply with these guidelines in a clinical setting. Firstly, besides being small, detection of HPs and SAs is also complicated by their predominantly flat shape, unremarkable colour and mucus coating which possibly increases polyp miss rates.^{19 32} Secondly, removal of all detected polyps during endoscopic surveillance sessions in HPS patients with a large quantity of polyps can be time-consuming and unfeasible, especially when endoscopic mucosal resection (EMR) is indicated for predominantly flat serrated polyps.

With regard to polyp detection, previous randomised controlled trials demonstrated that chromoendoscopy and narrow-band imaging (NBI) increased the detection of HPs.^{33–38} Although not formally investigated, these techniques could in this respect also be of value for the detection of serrated polyps in HPS. Concerning polyp removal, the multiplicity of polyps and the use of EMR can indeed lead to increased duration of endoscopic procedures in patients with HPS. In this respect, it is important that these endoscopies are performed by endoscopists experienced in EMR for complete, prompt and safe polyp removal and that allowances are made for sufficient procedure time. Annual surveillance by an experienced endoscopist specialised in HPS, having advanced imaging techniques available such as chromoendoscopy and NBI seems therefore advisable. Alternatively, when complete endoscopic removal of all polyps is not feasible, surgical colonic resection should seriously be considered since these patients have an increased risk of malignant progression of polyps.

In this study, at multivariate logistic regression, an increasing number of HPs and SAs was significantly associated with CRC presence (OR of 1.05 and 1.09 respectively per polyp). In other words, the CRC risk will increase by 5% and 9% respectively with each additional HP or SA. Concordantly, results from previous literature reports strongly suggest that SAs in particular play a role in a 'serrated pathway' leading to CRC in HPS.^{19 39–41} A possible explanation for the significant association between HPs and CRC in this study could be that HPs and SAs (primarily sessile serrated adenomas) are histologically hard to distinguish, leading to incorrect differentiation and misdiagnosis of these serrated polyps. Indeed, it has recently been

shown that even at re-evaluation the interobserver agreement for the differentiation of serrated polyps remains only moderate ($\kappa=0.55$).^{14 15 42} Nevertheless, the significant association between serrated polyps and CRC in this study supports the hypothesis of a 'serrated pathway' leading to CRC in HPS (figure 2).

In conclusion, HPS is associated with an increased personal CRC risk, even under endoscopic surveillance. Considering that these advanced lesions were detected in polyps as small as 4 mm (median: 10 mm), which were not recognised as such, all polyps in HPS seem at risk of representing advanced lesions warranting

removal of all polyps. However, the miss rate of polyps <10 mm (which represents the majority of polyps in HPS) has been shown to be as high as 23% with standard white-light endoscopy suggesting that a considerable number of polyps in HPS are missed.²⁶ Advanced endoscopic imaging techniques such as chromoendoscopy and NBI may in this respect be of additional value for the detection of polyps in HPS. Alternatively, if endoscopically unfeasible, preventive colonic resection should be considered. An increasing number of serrated polyps are associated with the presence of CRC in HPS, supporting the theory of a 'serrated pathway' leading to CRC. Future prospective data from large HPS cohorts, undergoing a standardised treatment protocol are required to further enhance our knowledge with regard to the rate of polyp progression in these patients and to determine the optimal treatment and surveillance protocol for these patients.

Competing interests None.

Ethics approval This study was conducted in accordance with the research code of our institutional medical ethics committee on human experimentation, as well as in agreement with the Helsinki Declaration of 1975, as revised in 1983.

Provenance and peer review Not commissioned; externally peer reviewed.

REFERENCES

1. Jemal A, Thun MJ, Ries LA, *et al.* Annual report to the nation on the status of cancer, 1975–2005, featuring trends in lung cancer, tobacco use, and tobacco control. *J Natl Cancer Inst* 2008;**100**:1672–94.
2. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. *Cell* 1990;**61**:759–67.
3. Vogelstein B, Fearon ER, Hamilton SR, *et al.* Genetic alterations during colorectal-tumor development. *N Engl J Med* 1988;**319**:525–32.
4. Makinen MJ. Colorectal serrated adenocarcinoma. *Histopathology* 2007;**50**:131–50.
5. Boparai KS, Dekker E, van Eeden S, *et al.* Hyperplastic polyps and sessile serrated adenomas as a phenotypic expression of MYH-associated polyposis. *Gastroenterology* 2008;**135**:2014–8.
6. Carvajal-Carmona L, Howarth K, Lockett M, *et al.* Molecular classification and genetic pathways in hyperplastic polyposis syndrome. *J Pathol* 2007;**212**:378–85.
7. Chow E, Lipton L, Lynch E, *et al.* Hyperplastic polyposis syndrome: phenotypic presentations and the role of MBD4 and MYH. *Gastroenterology* 2006;**131**:30–9.
8. Hyman NH, Anderson P, Blasyk H. Hyperplastic polyposis and the risk of colorectal cancer. *Dis Colon Rectum* 2004;**47**:2101–4.
9. Iino H, Jass JR, Simms LA, *et al.* DNA microsatellite instability in hyperplastic polyps, serrated adenomas, and mixed polyps: a mild mutator pathway for colorectal cancer? *J Clin Pathol* 1999;**52**:5–9.
10. Jass JR, Iino H, Ruzsiewicz A, *et al.* Neoplastic progression occurs through mutator pathways in hyperplastic polyposis of the colorectum. *Gut* 2000;**47**:43–9.
11. Rashid A, Houlihan PS, Booker S, *et al.* Phenotypic and molecular characteristics of hyperplastic polyposis. *Gastroenterology* 2000;**119**:323–32.
12. Rubio CA, Stemme S, Jaramillo E, *et al.* Hyperplastic polyposis coli syndrome and colorectal carcinoma. *Endoscopy* 2006;**38**:266–70.
13. East JE, Saunders BP, Jass JR. Sporadic and syndromic hyperplastic polyps and serrated adenomas of the colon: classification, molecular genetics, natural history, and clinical management. *Gastroenterol Clin North Am* 2008;**37**:25–46 v.
14. Farris AB, Misraji J, Srivastava A, *et al.* Sessile serrated adenoma: challenging discrimination from other serrated colonic polyps. *Am J Surg Pathol* 2008;**32**:30–5.
15. Sandmeier D, Seelentag W, Bouzourene H. Serrated polyps of the colorectum: is sessile serrated adenoma distinguishable from hyperplastic polyp in a daily practice? *Virchows Arch* 2007;**450**:613–8.
16. Torlakovic E, Skovlund E, Snover DC, *et al.* Morphologic reappraisal of serrated colorectal polyps. *Am J Surg Pathol* 2003;**27**:65–81.
17. Snover DC, Jass JR, Fenoglio-Preiser C, *et al.* Serrated polyps of the large intestine: a morphologic and molecular review of an evolving concept. *Am J Clin Pathol* 2005;**124**:380–91.
18. Winawer S, Fletcher R, Rex D, *et al.* Colorectal cancer screening and surveillance: clinical guidelines and rationale-update based on new evidence. *Gastroenterology* 2003;**124**:544–60.
19. Spring KJ, Zhao ZZ, Karamatic R, *et al.* High prevalence of sessile serrated adenomas with BRAF mutations: a prospective study of patients undergoing colonoscopy. *Gastroenterology* 2006;**131**:1400–7.
20. DiSario JA, Foutch PG, Mai HD, *et al.* Prevalence and malignant potential of colorectal polyps in asymptomatic, average-risk men. *Am J Gastroenterol* 1991;**86**:941–5.




Figure 2 Endoscopic image of a serrated adenoma (10 mm, ascending colon) detected in a patient with hyperplastic polyposis syndrome (A). At microscopy a focus of adenocarcinoma was seen within the serrated adenoma (B,C).

Colon

21. Estrada RG, Spijt HJ. Hyperplastic polyps of the large bowel. *Am J Surg Pathol* 1980;**4**:127–33.
22. Hayashi T, Yatani R, Apostol J, *et al*. Pathogenesis of hyperplastic polyps of the colon: a hypothesis based on ultrastructure and in vitro cell kinetics. *Gastroenterology* 1974;**66**:347–56.
23. Imperiale TF, Wagner DR, Lin CY, *et al*. Results of screening colonoscopy among persons 40 to 49 years of age. *N Engl J Med* 2002;**346**:1781–5.
24. Johnson DA, Gurney MS, Volpe RJ, *et al*. A prospective study of the prevalence of colonic neoplasms in asymptomatic patients with an age-related risk. *Am J Gastroenterol* 1990;**85**:969–74.
25. Lieberman DA, Prindiville S, Weiss DG, *et al*. Risk factors for advanced colonic neoplasia and hyperplastic polyps in asymptomatic individuals. *JAMA* 2003;**290**:2959–67.
26. van Rijn JC, Reitsma JB, Stoker J, *et al*. Polyp miss rate determined by tandem colonoscopy: a systematic review. *Am J Gastroenterol* 2006;**101**:343–50.
27. Lazarus R, Junttila OE, Karttunen TJ, *et al*. The risk of metachronous neoplasia in patients with serrated adenoma. *Am J Clin Pathol* 2005;**123**:349–59.
28. Oono JE, Suzuki N, Saunders BP. Progression of a sessile serrated adenoma to an early invasive cancer within 8 months. *Dig Dis Sci* 2008;**54**:906–9.
29. Butterly LF, Chase MP, Pohl H, *et al*. Prevalence of clinically important histology in small adenomas. *Clin Gastroenterol Hepatol* 2006;**4**:343–8.
30. East JE, Suzuki N, Saunders BP. Comparison of magnified pit pattern interpretation with narrow band imaging versus chromoendoscopy for diminutive colonic polyps: a pilot study. *Gastrointest Endosc* 2007;**66**:310–6.
31. Sano Y, Ikematsu H, Fu KI, *et al*. Meshed capillary vessels by use of narrow-band imaging for differential diagnosis of small colorectal polyps. *Gastrointest Endosc* 2008;**69**:278–83.
32. Yano T, Sano Y, Iwasaki J, *et al*. Distribution and prevalence of colorectal hyperplastic polyps using magnifying pan-mucosal chromoendoscopy and its relationship with synchronous colorectal cancer: prospective study. *J Gastroenterol Hepatol* 2005;**20**:1572–7.
33. Kiesslich R, von BM, Hahn M, *et al*. Chromoendoscopy with indigocarmine improves the detection of adenomatous and nonadenomatous lesions in the colon. *Endoscopy* 2001;**33**:1001–6.
34. Lecomte T, Cellier C, Meatchi T, *et al*. Chromoendoscopic colonoscopy for detecting preneoplastic lesions in hereditary nonpolyposis colorectal cancer syndrome. *Clin Gastroenterol Hepatol* 2005;**3**:897–902.
35. Lee JH, Kim JW, Cho YK, *et al*. Detection of colorectal adenomas by routine chromoendoscopy with indigocarmine. *Am J Gastroenterol* 2003;**98**:1284–8.
36. Ratiu N, Gelbmann C, Rath HR, *et al*. Chromoendoscopy with indigo carmine in flexible sigmoidoscopy screening: does it improve the detection of adenomas in the distal colon and rectum? *J Gastrointest Liver Dis* 2007;**16**:153–6.
37. Adler A, Aschenbeck J, Yenerim T, *et al*. Narrow-band versus white-light high definition television endoscopic imaging for screening colonoscopy: a prospective randomized trial. *Gastroenterology* 2008;**136**:410–6.
38. Kaltenbach T, Friedland S, Soetikno R. A randomised tandem colonoscopy trial of narrow band imaging versus white light examination to compare neoplasia miss rates. *Gut* 2008;**57**:1406–12.
39. Jass JR, Baker K, Zlobec I, *et al*. Advanced colorectal polyps with the molecular and morphological features of serrated polyps and adenomas: concept of a 'fusion' pathway to colorectal cancer. *Histopathology* 2006;**49**:121–31.
40. Kambara T, Simms LA, Whitehall VL, *et al*. BRAF mutation is associated with DNA methylation in serrated polyps and cancers of the colorectum. *Gut* 2004;**53**:1137–44.
41. Minoo P, Baker K, Goswami R, *et al*. Extensive DNA methylation in normal colorectal mucosa in hyperplastic polyposis. *Gut* 2006;**55**:1467–74.
42. Torlakovic E, Snover DC. Serrated adenomatous polyposis in humans. *Gastroenterology* 1996;**110**:748–55.

Editor's quiz: GI snapshot

ANSWER

From the question on page 1036

The patient was treated with intravenous ceftriaxone at a dose of 1 g every 12 h. Ceftriaxone is partially excreted in the bile where it can be concentrated in the gallbladder and precipitate as a ceftriaxone–calcium salt in a process termed biliary



Figure 1 CT showing complete resolution of biliary pseudolithiasis with a normal gallbladder 2 months after stopping ceftriaxone.

pseudolithiasis.¹ This process typically reverses quickly after stopping ceftriaxone and is usually asymptomatic.² Rarely, patients can develop cholecystitis, cholangitis or biliary pancreatitis and may require surgical or endoscopic management.³

In our patient, ceftriaxone was discontinued and 2 months later a follow-up CT scan (figure 1) and ultrasound showed a completely normal gallbladder. This case well-illustrates a common side effect of ceftriaxone that should be remembered by all who prescribe this antibiotic and by all who routinely treat gallbladder disease.

Gut 2010;**59**:1100. doi:10.1136/gut.2009.188276a

REFERENCES

1. Park H, Lee S, Schy A. Ceftriaxone-associated gallbladder sludge. Identification of calcium-ceftriaxone salt as a major component of gallbladder precipitate. *Gastroenterology* 1991;**100**:1665–70.
2. Soysal A, Erasov K, Akpinar I, *et al*. Biliary precipitation during ceftriaxone therapy: frequency and risk factors. *Turk J Pediatr* 2007;**49**:404–7.
3. Sasaki Y, Aoki S, Aoki K, *et al*. Acute pancreatitis associated with the administration of ceftriaxone in an adult patient. *Nippon Shokakibyo Gakkai Zasshi* 2009;**106**:569–75.



Increased colorectal cancer risk during follow-up in patients with hyperplastic polyposis syndrome: a multicentre cohort study

Karam S Boparai, Elisabeth M H Mathus-Vliegen, Jan J Koornstra, et al.

Gut 2010 59: 1094-1100 originally published online August 25, 2009
doi: 10.1136/gut.2009.185884

Updated information and services can be found at:

<http://gut.bmj.com/content/59/8/1094.full.html>

These include:

References

This article cites 42 articles, 9 of which can be accessed free at:

<http://gut.bmj.com/content/59/8/1094.full.html#ref-list-1>

Article cited in:

<http://gut.bmj.com/content/59/8/1094.full.html#related-urls>

Email alerting service

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections

Articles on similar topics can be found in the following collections

[Colon cancer](#) (2889 articles)

Notes

To request permissions go to:

<http://group.bmj.com/group/rights-licensing/permissions>

To order reprints go to:

<http://journals.bmj.com/cgi/reprintform>

To subscribe to BMJ go to:

<http://group.bmj.com/subscribe/>